Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HHH NASDAQ:LNTH NASDAQ:PTCT NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$70.40-2.3%$67.61$61.01▼$91.07$4.30B1.12343,085 shs401,061 shsLNTHLantheus$107.59+2.4%$102.40$47.25▼$111.86$6.84B-0.06852,959 shs1.12 million shsPTCTPTC Therapeutics$78.59+0.1%$76.77$43.17▼$90.87$6.51B0.532.17 million shs704,131 shsTSHATaysha Gene Therapies$5.96-0.2%$6.06$2.34▼$7.30$1.72B1.174.03 million shs2.85 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes-2.37%-2.22%+5.94%+6.71%+2.09%LNTHLantheus+2.36%+1.85%+4.26%+28.36%+44.59%PTCTPTC Therapeutics+0.09%-7.38%+0.08%+8.50%+63.25%TSHATaysha Gene Therapies-0.17%-5.99%-3.72%-7.31%+134.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$70.40-2.3%$67.61$61.01▼$91.07$4.30B1.12343,085 shs401,061 shsLNTHLantheus$107.59+2.4%$102.40$47.25▼$111.86$6.84B-0.06852,959 shs1.12 million shsPTCTPTC Therapeutics$78.59+0.1%$76.77$43.17▼$90.87$6.51B0.532.17 million shs704,131 shsTSHATaysha Gene Therapies$5.96-0.2%$6.06$2.34▼$7.30$1.72B1.174.03 million shs2.85 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes-2.37%-2.22%+5.94%+6.71%+2.09%LNTHLantheus+2.36%+1.85%+4.26%+28.36%+44.59%PTCTPTC Therapeutics+0.09%-7.38%+0.08%+8.50%+63.25%TSHATaysha Gene Therapies-0.17%-5.99%-3.72%-7.31%+134.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHHHHoward Hughes 1.67Reduce$79.0012.22% UpsideLNTHLantheus 2.73Moderate Buy$110.432.64% UpsidePTCTPTC Therapeutics 2.80Moderate Buy$92.4317.61% UpsideTSHATaysha Gene Therapies 3.00Buy$12.62111.67% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, LNTH, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026HHHHoward Hughes JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$76.00 ➝ $79.007/16/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $125.007/16/2026PTCTPTC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$124.00 ➝ $130.007/15/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform ➝ Market Outperform$115.00 ➝ $120.007/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.007/7/2026PTCTPTC Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/2/2026TSHATaysha Gene Therapies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$11.006/30/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/30/2026TSHATaysha Gene Therapies Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.006/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.00(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHHHHoward Hughes$1.51B2.78$6.06 per share11.61$49.69 per share1.42LNTHLantheus$1.55B4.53$6.54 per share16.46$16.43 per share6.55PTCTPTC Therapeutics$1.73B3.77$8.78 per share8.95($2.56) per share-30.70TSHATaysha Gene Therapies$9.77M175.30N/AN/A$0.90 per share6.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHHHHoward Hughes$131.88M$2.0434.5120.65N/A8.04%5.41%1.61%N/ALNTHLantheus$233.56M$4.1525.9320.00N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A32.344.49-22.58%-362.45%-6.76%7/30/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest TSHA, HHH, LNTH, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026TSHATaysha Gene Therapies-$0.11N/AN/AN/A$0.62 millionN/A8/5/2026Q2 2026LNTHLantheus$1.33N/AN/AN/A$362.99 millionN/A7/30/2026Q2 2026PTCTPTC Therapeutics$0.28N/AN/AN/A$295.38 millionN/A5/7/2026Q1 2026HHHHoward Hughes$0.08$0.14+$0.06$0.14N/A$235.92 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHHHHoward HughesN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHHHHoward Hughes1.971.581.58LNTHLantheus0.472.832.64PTCTPTC TherapeuticsN/A2.442.36TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHHHHoward Hughes93.83%LNTHLantheus99.06%PTCTPTC TherapeuticsN/ATSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipHHHHoward Hughes48.00%LNTHLantheus1.70%PTCTPTC Therapeutics5.50%TSHATaysha Gene Therapies3.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHHHHoward Hughes60859.63 million31.01 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableTSHATaysha Gene Therapies180287.36 million277.36 millionOptionableTSHA, HHH, PTCT, and LNTH HeadlinesRecent News About These CompaniesTaysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest InJuly 15 at 6:09 PM | finance.yahoo.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 7.4% - Still a Buy?July 14, 2026 | marketbeat.comInsider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of StockJuly 11, 2026 | insidertrades.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of StockJuly 10, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.3% - What's Next?July 10, 2026 | marketbeat.comTaysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label PotentialJune 30, 2026 | seekingalpha.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 25, 2026 | finanznachrichten.deTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical ...June 25, 2026 | enidnews.comETaysha Gene Therapies Announces Major Equity Financing DealJune 25, 2026 | tipranks.comTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingJune 25, 2026 | globenewswire.comTaysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200MJune 25, 2026 | msn.comTaysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | quiverquant.comQTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and AbbVie (ABBV)June 23, 2026 | theglobeandmail.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - SlideshowJune 23, 2026 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome TranscriptJune 22, 2026 | seekingalpha.comTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 ...June 22, 2026 | markets.businessinsider.comTaysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)June 22, 2026 | msn.comTaysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year RecoveryJune 13, 2026 | finance.yahoo.comIs Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, PTCT, and LNTH Company DescriptionsHoward Hughes NYSE:HHH$70.40 -1.65 (-2.29%) Closing price 07/17/2026 03:59 PM EasternExtended Trading$71.15 +0.75 (+1.07%) As of 07/17/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Lantheus NASDAQ:LNTH$107.59 +2.48 (+2.36%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$107.50 -0.09 (-0.08%) As of 07/17/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.PTC Therapeutics NASDAQ:PTCT$78.59 +0.07 (+0.09%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$78.56 -0.03 (-0.04%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Taysha Gene Therapies NASDAQ:TSHA$5.96 -0.01 (-0.17%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$6.12 +0.16 (+2.65%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
